A pharmaceutical company that makes EpiPen and EpiPen Jr., Mylan Inc., has been ordered to pay a $465 million nationwide settlement for knowingly avoiding the payment of rebates to Medicaid programs. Kentucky's portion of the settlement is $12.2 million.
Attorney General Andy Beshear said $8.5 million will be returned to the federal Medicaid program and $3.7 million will be returned to Kentucky’s program. The federal government pays about 70 percent of Medicaid costs in the state.
Federal law requires makers of brand-name drugs to pay higher rebates to Medicaid, and Mylan was found to have avoided paying these higher rebates by improperly classifying the brand name drug as a generic one.
Attorney General Andy Beshear said $8.5 million will be returned to the federal Medicaid program and $3.7 million will be returned to Kentucky’s program. The federal government pays about 70 percent of Medicaid costs in the state.
Federal law requires makers of brand-name drugs to pay higher rebates to Medicaid, and Mylan was found to have avoided paying these higher rebates by improperly classifying the brand name drug as a generic one.
No comments:
Post a Comment